ARTICLE / CLIENT ALERT
Final Rules Issued on Reviews of Foreign Investments in the United States – CFIUS
January 23, 2020
Read time: 8 min
The US Treasury Department published final regulations to implement FIRRMA, which greatly expanded the scope of CFIUS to review foreign investments in US businesses. The new rules clarify and revise proposed regulations issued by Treasury last September, and parties involved in any foreign investments in US businesses should carefully consider the application of these new rules.
On January 17, 2020, the US Treasury Department published final regulations to implement the Foreign Investment Risk Review Modernization Act of 2018 (FIRRMA), which greatly expanded the scope of the Committee on Foreign Investment in the United States (CFIUS) to review foreign investments in US businesses. The purpose for CFIUS reviews continues to be to determine if foreign investments in the United States pose US national security issues. The new rules clarify and revise proposed regulations issued by Treasury last September—see our previous On the Subject. The final regulations become effective on February 13, 2020.
Covered Control Transactions
Under FIRRMA and the new rules, CFIUS continues to have jurisdiction to review any transaction by or with any foreign person that could result in foreign control of any US business, including those carried out through a joint venture. The new rules continue as under existing rules to define “control” as the power— through ownership of a majority or dominant minority—to determine certain specified important operations of the US business. Any majority acquisition of a US business by a foreign entity would be a “covered control transaction” that continues to be within the scope of CFIUS’s review authority.
As discussed below, certain foreign investments, including covered control transactions, with substantial foreign interests and/or those involving certain types of US businesses, will now be subject to mandatory CFIUS review. Other covered control transactions will remain subject to CFIUS review upon voluntary notification, as under existing rules.
Covered Investments
Under FIRRMA and the final implementing regulations, certain non-controlling foreign investments in a US business will also be subject to CFIUS review. The jurisdiction of CFIUS over such non-controlling investments is based on three factors: (1) the investor must be a “foreign person” or “foreign entity,” (2) the US business must have certain specified attributes, and (3) the foreign investor must have certain triggering rights in the US business.
1. The investor must be a foreign person. “Foreign persons” include foreign individuals, entities and governments along with entities that are controlled by foreign individuals or entities or in which a foreign government has a “substantial interest” of 49% of more.
As discussed below, FIRRMA imposes mandatory reviews for certain foreign investments. The final regulations carve out from mandatory filing requirements investments involving “excepted investors” from “excepted foreign states.” Treasury has initially designated only Australia, Canada and the United Kingdom as excepted foreign states for two years, through February 12, 2022. Investments in US businesses by nationals of these countries can still be reviewed by CFIUS at its discretion.
Under the final regulations, an “excepted investor” is one with at least 75% of its board members who are either US nationals or from an excepted foreign state. Foreign individual investors may be treated as excepted investors if they acquire no more than 10% of the US business.
2. The US business must have certain attributes. The foreign investor must invest in a “TID US Business”—a US business with critical Technology, critical Infrastructure or sensitive personal Data, as follows:
The production, development or testing of “critical technologies”:
- Critical technologies are defined in FIRRMA generally as those technologies subject to US export license requirements under various US export control laws. The final regulations continue to reflect this definition, which includes “emerging” and “foundational” technologies that remain subject to review and further definition by the US Commerce Department.
- The CFIUS Pilot Program, implemented in 2018 in Part 801 of the CFIUS regulations, imposed mandatory filing requirements for foreign investments in US businesses with critical technologies involving certain specified industries. The Pilot Program will end February 13, 2020, when the final regulations take effect, but the substance of the Pilot Program, including the mandatory filing requirement, has been largely maintained in the final regulations. CFIUS anticipates issuing additional proposed rules in the future that that would revise the mandatory review requirement from one based on specified industries (referenced by NAICS codes) to one based on export control license requirements.
The operation or ownership of “critical infrastructure”:
- The final rules continue to define critical infrastructure as systems and assets so vital to the United States that their incapacity or destruction would have a debilitating impact on national security.
- Like the proposed rules, the final regulations include an Appendix A that specifies the scope and operations of covered critical infrastructure, including internet network systems, telecommunication systems, submarine cable systems, specialty metals, defense production resources and others.
The collection or possession of “sensitive personal data” on US citizens:
- Sensitive personal data covers identifiable data on individual US citizens in 10 specified categories, including health, financial and geolocation, among others.
A US business with these categories of data will be covered by the rules only if:
- It targets or tailors products or services to certain populations (g., US military or national security employees), or
- It maintains or expressly seeks to maintain such data on at least one million individuals.
- Genetic test information is covered whether or not it meets the foregoing conditions.
3. The foreign investor must attain certain triggering rights in the US business. The foreign investor must receive one or more of the following rights in the US business:
- Access to material nonpublic technical information regarding critical infrastructure or critical technology;
- Seats, nomination rights, or observer rights on the board; or
- Involvement in substantive decision-making of the US business regarding sensitive personal data, critical technology or critical infrastructure.
Mandatory and Voluntary Declarations
Parties to covered transactions are required to notify CFIUS and seek a review, either by filing a short-form declaration or a full notice, if the foreign investment in a US business meets the following criteria:
- The foreign investor gains a 25% or greater interest in a TID US Business and such foreign investor is itself owned 49% or more by a foreign government, other than an excepted state, currently including Canada, Australia and the UK.
- The foreign investor invests (in any amount) with the foregoing triggering rights in a TID US business that utilizes critical technologies itself in an industry specified in Appendix B to the new rules, or that designs any critical technologies specifically for use in one or more of those specified industries in Appendix B.
- Note that Treasury intends to issue a revised rule at a later date that would replace the NAICS industry basis for the mandatory filing requirement with one based on specific export license requirements for the critical technology.
The final regulations allow parties to file voluntary declarations, rather than full notices, in certain types of transactions. Parties may consider voluntarily filing such short-form declarations, which generally are easier and possibly faster than full notices, for covered transactions that they consider pose no likely US national security issues.
A mandatory declaration must be filed at least 30 days prior to the closing of the transaction.
Special Note on Investment Funds
Under existing and proposed regulations, certain exceptions to CFIUS jurisdiction were made for selected types of foreign investments by funds investing in US businesses. However, these regulations were vague and created uncertainty for fund investors. The final regulations clarify the “investment fund exception” in the following two respects.
First, the regulations provide that CFIUS will determine the foreign status of a fund depending on the location “where the fund’s activities and investments are primarily directed, controlled, or coordinated by the general partner, managing member, or equivalent.” However, if the entity has represented its primary place of business as outside the United States, that location will determine its status as a “foreign entity” unless it can show otherwise.
Second, the regulations clarify that an investment by a foreign person in an investment fund that invests in a US business will not be considered a covered investment, as long as the fund is managed by a US general partner and the foreign investor’s rights are sufficiently limited.
Covered Real Estate Transactions
Treasury issued final FIRRMA regulations under new Part 802 of the CFIUS rules, to extend CFIUS review jurisdiction over certain real estate transactions. CFIUS will have the discretion to review, with some exceptions, any real estate transaction in which a foreign investor buys, leases or obtains a concession with respect to “covered real estate.”
The regulations define covered real estate as property:
- Within most US air or maritime ports, or
- Within close proximity to certain US facilities or military installations specified in Appendix A to the regulations.
In order to be a covered real estate transaction, the foreign investor must attain three or more of the following property rights: to access, to exclude access, to improve or develop, or to affix structures or immovable objects.
Mandatory declarations are not required for covered real estate transactions.
Takeaways
The final CFIUS rules impose new and complex definitions, policies and requirements. FIRRMA also authorized CFIUS to impose a filing fee, but Treasury states it will publish a separate rule for that at a later date. Parties involved in any foreign investments in US businesses should carefully consider the application of these new rules, including whether a mandatory filing and review is required.
When It’s All in the Family: Reverse Confusion Not a Basis for Broad Trademark Remedies
ARTICLE
When It’s All in the Family: Reverse Confusion Not a Basis for Broad Trademark Remedies
January 23, 2020
Read time: 1 min

Ninth Circuit Affirms Sale of Trustee’s Litigation Claims to Self-Interested Party
ARTICLE / CLIENT ALERT
Ninth Circuit Affirms Sale of Trustee’s Litigation Claims to Self-Interested Party
January 22, 2020
Read time: 8 min
A bankruptcy trustee may sell “avoidance powers to a self-interested party that will abandon those claims, so long as the overall value obtained for the transfer is appropriate,” held the U.S. Court of Appeals for the Ninth Circuit on Jan. 15, 2020. Silverman v. Birdsell, 2020 WL 236777, *1 (9th Cir. Jan. 15, 2020). Affirming the lower courts, the Ninth Circuit reaffirmed its prior holding that “a bankruptcy trustee may sell an estate’s avoidance claims to a creditor when ‘the creditor is pursuing interests common to all creditors’ and ‘allowing the creditor to exercise those powers will benefit the remaining creditors.’” Id., quoting In re PRTC, Inc., 177 F.3d 774, 782 (9th Cir. 1999) and Briggs v. Kent, 955 F.2d 623, 626 (9th Cir. 1992) (“If a creditor is pursuing interests common to all creditors…, he may exercise the trustee’s avoiding powers.”). In Silverman, the court-approved sale was “expected to result in abandonment of the claims by transferring them to the would-be defendant.” Id.
Relevance
Courts and commentators have questioned the propriety of granting Chapter 11 debtor in possession (“DIP”) financing lenders a lien on avoidance recovery actions (e.g., preferences, fraudulent transfers), another form of “transfer” under Bankruptcy Code (“Code”) §101(54)(A) (“… ‘transfer’ means… the creation of a lien.”). See In re Qualitech Steel Corp., 276 F.3d 245, 248 (7th Cir. 2001) (“courts do not favor using [Code] §364 to give pre-petition lenders security interests in the proceeds of avoidance actions.”); See also U.S. Bankruptcy Court Southern District of New York Rule 4001-2(a), (g)(9) (movant must “prominently highlight …” any provision in financing order for liens on proceeds of avoidance action and any such provision will be “deemed denied” unless “expressly and separately addressed by the court”; Del. Bankr. L. R. 4001-2(a)(i)(D) (provisions that grant immediately to the prepetition secured creditor liens on “the debtor’s claims and causes of action under [Code] §§ 544, 545, 547, 548 and 549” must be “highlighted” and recite “whether the proposed form of order and/or underlying cash collateral stipulation or loan agreement contains any [such] provision …, identify the location of any such provision in the proposed form of order, cash collateral stipulation and/or loan agreement, and … justify the inclusion of such provision”; “[i]n the absence of extraordinary circumstances, the Court shall not approve interim financing orders that include” liens on avoidance action provisions); 3 Collier, Bankruptcy ¶364.06[6] at 364-31, 364-32 (16th ed. 2019) (“… such liens encumber potentially significant assets that would otherwise be available for the benefit of all unsecured creditors” — “can be controversial”.).
Facts
The bankruptcy court had granted the motion of the trustee to sell to K certain of his “avoidance claims and related litigation claims held by” the debtor. Silverman, 2020 WL 236777, at *1. After the district court affirmed, certain creditors appealed, arguing that the sale was improper because K “is not pursing interests common to all stakeholders and its use of those powers will not benefit all stakeholders; … even if the sale was not improper on this ground, the bankruptcy court abused its discretion because it failed to fully evaluate [a] competing proposal …” Id.
Ninth Circuit Analysis
The Ninth Circuit reaffirmed its prior holding in PRTC but, said the court, nothing in that decision “suggests that the analysis is the same when, as here, the sale is expected to result in abandonment of the claims by transferring them to the would-be defendant.” Id. Still, reasoned the court, “nothing in … PRTC precludes transferring the trustee’s avoidance powers to a self-interested party that will abandon those claims, so long as the overall value obtained for the transfer is appropriate.” Id. As the Bankruptcy Appellate Panel in another case recognized, “PRTC stands for the simple proposition that a trustee’s ‘avoiding powers may be transferred for a sum certain.’” In re Lahijani, 325B.R.282, 288 (BAP 9th Cir. 2005).
The Ninth Circuit stressed that it had “never categorically prohibited the type of sale approved by the Bankruptcy Court here.” Silverman 2020 WL 236777 at *1. Nevertheless, when a bankruptcy court “authorizes the sale of the estate’s litigation claims to the would be defendant of those claims, … [it] must analyze the sale under both [Code] §363(b)(1) and Fed. R. Bankr. P. Rule 9019.” Id. at *2, citing Lahijani, 325B.R. at 288-91. When applying §363, the court must “assure that optimal value is realized by the estate under the circumstances.” Id. In comparing K’s cash bid for the claims to the objecting parties’ motion, the bankruptcy court had questioned whether any person “would succeed in litigating the estate’s claims,” reflecting the conclusion that the cash bid was superior. Id. According to the court, the bankruptcy court had been familiar “with the extended litigation history between the parties” and had carefully considered “the relevant factors.” Id.
The bankruptcy court had also considered all the relevant criteria when applying Bankruptcy Rule 9019 for approval of a settlement. It considered “(a) the probability of success in the litigation; (b) the difficulties, if any, to be encountered in the matter of collection; (c) the complexity of litigation involved, and the expense, inconvenience and delay necessarily attending it; and (d) the paramount interest of the creditors and a proper deference to their reasonable views ….” Id., quoting and citing In re Mickey Thompson Entm’t Grp., Inc., 292 B.R. 415, 420 (BAP 9th Cir. 2003) and In re A&C Props., 784 F.2d 1377, 1382 (9th Cir. 1986).
Liens on Avoiding Power Actions
Silverman dealt with the outright sale of avoidance power claims. Because granting a DIP lender a lien on these claims is also a transfer under Code §101(54)(A), Silverman is most relevant.
As noted, the Seventh Circuit had addressed the propriety of granting a DIP lender lien on avoidance actions in Qualitech. In that case, undersecured creditors received a replacement lien on avoidance actions over the opposition of certain creditors. When the debtor had filed its Chapter 11 Petition in March 1999, secured lenders had liens on all the debtor’s assets, securing about $265 million in claims. 276 F.3d at 246. Management estimated the value of the debtor’s assets at $225 million as of the bankruptcy filing. Id. Although the lenders were undersecured and the debtor was losing $10 million a month, certain of the lenders agreed to keep the debtor operating with a $30 million super priority DIP financing, which “required demoting the [preexisting] secured lender’s positon and substituting new security under [Code] §364(d)(1). The only other assets in sight were the proceeds of preference recovery actions …. [T]he bankruptcy court approved … financing of $30 million, with super security and an award of replacement security to the [primed] senior lenders, to the extent that this was necessary to maintain their financial positon. No one appealed or sought a stay.” Id. at 247.
The debtor’s assets were sold five months after the financing for approximately $180 million. Id. The first $30 million went to the DIP lenders, “leaving $150 million for the old secured creditors,” who relied on the provision in the financing order giving them “extra security — first dibs in the preference recovery kitty, which would make up some but far from all the loss.” Id.
The creditors’ committee in Qualitech argued, of course, that pre-bankruptcy lenders should not receive security interests in the proceeds of avoidance actions and that the secured lenders had improved their positon as a result of the DIP financing. Id. at 248. “But the bankruptcy judge concluded that good money had been thrown after bad, the secured lenders’ position had been eroded by at least the value of the anticipated preference recoveries, and that they therefore were entitled to a substitute security interest in that collateral.” Id. at 247.
The district court and the court of appeals affirmed. The Seventh Circuit held that it was “too late to tell” the primed lenders “that they, rather than the unsecured creditors, must swallow” any loss resulting from the DIP financing. Id. at 248. According to the Seventh Circuit, “the secured creditors suffered a loss as a result of the DIP financing,” which “entitled [them] to” the preference recoveries under Code § 364(d)(1). Id. at 247. The court’s reasoning is significant:
… [At the beginning of the case] in March 1999 the secured creditors had interests worth $225 million, yet … in August 1999 these interests were worth, at most, $197 million after paying off the DIP lenders…. [T]he secured lenders lost more than the value of the avoidance actions on any calculation.
Id. at 248.
Comment
The Ninth Circuit took a sensible, pragmatic approach in Silverman. Following general maxims to bar the transfer of litigation claims – whether by sale or by granting a lien – would cause a debtor’s estate to lose value. So long as the court, after notice and a hearing, is able to evaluate the business justification for the proposed transfer, the “optimal” value of avoiding power actions can be realized.
Authored by Michael L. Cook.
If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or the author.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.
The Sprint to Modernize and Clarify the Stark Law—Part II
ARTICLE
The Sprint to Modernize and Clarify the Stark Law—Part II
January 2020
Read time: 1 min
Key Takeaways from OIG’s AKS Sprint Proposed Rule
ARTICLE
Key Takeaways from OIG’s AKS Sprint Proposed Rule
January 2020
Read time: 1 min
California Bill Proposes CCPA Exceptions for HIPAA De-identified Information, Other Health Data
ARTICLE / CLIENT ALERT
California Bill Proposes CCPA Exceptions for HIPAA De-identified Information, Other Health Data
January 17, 2020
Read time: 6 min
The California State Senate’s Health Committee recently approved California AB 713, which would amend the California Consumer Privacy Act (CCPA) to except from CCPA requirements additional categories of health information, including data de-identified in accordance with HIPAA and certain medical research data. If enacted, the bill would simplify CCPA compliance strategies for many HIPAA-regulated entities, life sciences companies, research institutions and data aggregators.
On January 6, 2020, the California State Senate’s Health Committee unanimously approved California AB 713, a bill that would amend the California Consumer Privacy Act (CCPA) to except from CCPA requirements additional categories of health information, including data de-identified in accordance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA), medical research data, personal information used for public health and safety activities, and patient information that is maintained by HIPAA business associates in the same manner as HIPAA protected health information (PHI). If enacted, the bill would simplify CCPA compliance strategies for many HIPAA-regulated entities, life sciences companies, research institutions and health data aggregators.
Exemption for HIPAA Business Associates
Presently, the CCPA does not regulate PHI that is collected by either a HIPAA covered entity or business associate.
The CCPA also exempts covered entities to the extent that they maintain patient information in the same manner as PHI subject to HIPAA. The CCPA does not, however, currently include a similar entity-based exemption for business associates.
AB 713 would add an exemption for business associates to the extent that they maintain, use and disclose patient information consistent with HIPAA requirements applicable to PHI. For example, if a business associate maintains consumer-generated health information that is not PHI, but processes the information in accordance with HIPAA requirements for PHI, then the information would not be regulated by the CCPA. While the practical import of the new exemption may be limited because business associates may not want to apply HIPAA requirements to consumer-generated health information, AB 713 offers business associates another potential exception to CCPA requirements for patient information about California consumers.
Exception for De-Identified Health Information
AB 713 would except from CCPA requirements de-identified health information when each of the following three conditions are met:
- The information is de-identified in accordance with a HIPAA de-identification method (i.e., the safe harbor or expert determination method) at 45 CFR § 164.514(b).
- The information is derived from PHI or “individually identifiable health information” under HIPAA, “medical information” as defined by the California Confidentiality of Medical Information Act (CMIA), or “identifiable private information” subject to the Common Rule.
- The business (or its business associate) does not actually, or attempt to, re-identify the information.
By explicitly providing that the CCPA does not apply to HIPAA de-identified information, AB 713 would alleviate the compliance challenges posed by potential inconsistencies between the HIPAA de-identification standard and the CCPA’s definition of de-identified information. Currently, it is not clear whether HIPAA de-identified information would also be considered de-identified under the CCPA. For a detailed analysis of the potential disconnect between the HIPAA and CCPA de-identification standards and possible compliance strategies, please see McDermott’s recent On the Subject.
Because the exception for de-identified information under AB 713 applies to de-identified information rather than HIPAA covered entities or business associates, the exception would be available to businesses that are not HIPAA-regulated entities but create de-identified data sets in accordance with the HIPAA de-identification standard and otherwise meet the three conditions above. For instance, this exception could be available to a research institution or life sciences company that is subject to the Common Rule or CMIA, but is not regulated by HIPAA, when it de-identifies identifiable private information or medical information and does not subsequently re-identify the resulting de-identified data set.
Exceptions for Personal Information Used in Research
The CCPA currently does not apply to personal information collected as part of a clinical trial subject to Common Rule, the International Council for Harmonization’s good clinical practice guidelines, or the US Food and Drug Administration’s (FDA’s) human subject protection requirements.
AB 713 would create additional CCPA exceptions for personal information that a business collects for, or uses in:
- Biomedical research studies that are subject to institutional review board standards, the Common Rule’s ethics and privacy requirements, the International Council for Harmonization’s good clinical practice guidelines, or the FDA’s human subject protection requirements
- Any research, subject to all applicable ethics and privacy laws, if the information is either “individually identifiable health information” under HIPAA or “medical information” as defined by the CMIA.
For the purposes of these research exceptions, AB 713 adopts the definition of “research” under HIPAA, which is a “systematic investigation, including research development, testing, and evaluation, designed to develop or contribute to generalizable knowledge.” The HIPAA definition is arguably broader than the CCPA definition of “research” as used in other CCPA provisions.
Exceptions for Personal Information Used for Public Health and Safety
AB 713 also creates partial CCPA exceptions for personal information used by a business in connection with certain public health and safety activities, so long as the business protects the privacy of the information under other applicable federal or state privacy laws and does not sell or use the information for other purposes. These activities are:
- Registration and tracking of products in accordance with applicable FDA regulations and guidance
- Public health activities and purposes as described in the HIPAA Privacy Rule at 45 CFR § 164.512
- FDA-regulated activities related to quality, safety or effectiveness.
AB 713 would still require a business to comply with certain CCPA requirements, such as those relating to consumer notice and access, with respect to personal information used for public health and safety activities.
New Privacy Notice Requirements
While AB 713 provides that the CCPA does not apply to de-identified information, it would still impose transparency requirements on a business that sells or discloses de-identified information. Namely, AB 713 requires a business to disclose in a consumer-facing privacy notice the following information:
- Whether the business discloses de-identified health information derived from “personal information” under the CCPA to third-parties
- Whether the business used the HIPAA safe harbor or expert determination method to create the de-identified health information.
If AB 713 becomes law, it would reduce CCPA compliance burdens for many life sciences companies, research organizations and other health care businesses by eliminating potential conflicts between the HIPAA and CCPA de-identification standards and excepting additional categories of health information from the CCPA.
Real Estate 2020
ARTICLE
Real Estate 2020
January 2020
Read time: 2 min
Maximilian Clostermeyer authored this chapter on real estate regulations in Germany and answers common questions involving land records, protection against liability and acquisitions.
Reproduced with permission from Law Business Research Ltd. This article was first published in Lexology Getting the Deal Through – Real Estate 2020 (Published: January 2020). For further information please visit www.gettingthedealthrough.com

Mandamus Denied: Need to Show Abuse of Discretion in Addition to Prejudice from Delay
ARTICLE
Mandamus Denied: Need to Show Abuse of Discretion in Addition to Prejudice from Delay
January 15, 2020
Read time: 3 min
Addressing an emergency request for a writ of mandamus to compel discovery of electronically stored information, the US Court of Appeals for the Sixth Circuit declined to set aside a district court’s denial of a request to create forensic images of all the defendant’s business and personal computers and cell phones. In re FCA US LLC, Case No. 19-1923 (6th Cir. 2019) (per curiam).
FCA filed trade-secret misappropriation and other claims against Patrea Bullock, a lawyer who formerly served as outside counsel to FCA. According to FCA, while serving as defense counsel, Bullock had access to extensive confidential and proprietary information belonging to FCA, including its “defense playbook.” After she resigned from her law firm, but before returning her computer, Bullock downloaded her files from the laptop onto several USB drives. Thereafter, she opened her own law firm representing plaintiffs against automobile manufacturers, including FCA. During discovery, Bullock produced 1,345 documents in response to FCA’s requests for the documents she had taken FCA, however, moved to compel a forensic image of all of Bullock’s business and personal laptops and cell phones so an expert could investigate what documents Bullock took.
The district court denied FCA’s forensic image request. Though acknowledging the importance of Bullock’s electronics to FCA’s case, the district court found that asserting a trade secret claim does not give a plaintiff free rein to examine all of the defendant’s electronics in search of evidence absent some more particularized need to do so. FCA requested emergency mandamus relief to compel the immediate forensic imaging.
The Sixth Circuit denied the writ. The Court concluded that FCA had “arguably established” that it could be permanently prejudiced by waiting to appeal until after final judgment because relevant data could be deliberately erased or disappear over time, even though civil litigants have a duty to preserve. The Court found, however, that FCA could not clear the hurdle to establish that the district court’s decision went so beyond an abuse of discretion as to warrant the extraordinary mandamus remedy. Nor could the alleged novelty of the question prompt issuance of the writ, given that courts have exhaustively analyzed discovery issues, including the permissible scope of discovery. Accordingly, the Court denied the writ of mandamus.
Practice Note: A writ of mandamus is an extraordinary remedy. The Court’s rejection of the writ here serves a broader purpose of ensuring that every discovery dispute does not morph into an appeal.
Modernizing FDA’s Data Strategy: Agency Announces March 27 Public Meeting, Requests Written Comments by End of April
ARTICLE / CLIENT ALERT
Modernizing FDA’s Data Strategy: Agency Announces March 27 Public Meeting, Requests Written Comments by End of April
January 15, 2020
Read time: 4 min
Modernizing FDA’s Data Strategy: Agency Announces March 27 Public Meeting, Requests Written Comments by End of April
On January 7, 2020, the US Food and Drug Administration (FDA) announced that it will hold a public meeting on March 27 to discuss possible Agency-level approaches to modernizing FDA’s data strategy, including approaches to data quality, data stewardship, data exchange and data analytics. Topics for discussion during the public meeting—and in written comments submitted to the parallel public docket—include the following:
Standards and policy, including:
- How can FDA best use policy and common data standards to help ensure the effective and efficient use of data assets?
- What are the consequences/issues as we move from ”static point-in-time data sets” to updating digital data streams for analyses?
- As we move into increased sharing and integrated data sets, how might FDA manage data in a way that avoids unnecessary duplication?
Data security, privacy and management including:
- How can FDA modernize its data strategy to continue ensuring privacy and security of data?
- What should FDA do to promote the management and organization of data assets across the Agency, as the amount and complexity of data (e.g., in regulatory submissions to FDA) is rapidly increasing?
Data strategies and data sharing, including:
- How can FDA’s data strategy facilitate broader goals of integration and interoperability of healthcare data, and scientific data/virtual patient data generated using scientific models?
- How can FDA design its data strategy to reflect a global marketplace and promote clarity to data providers like regulated industry and other stakeholders?
- How can FDA design its data strategy and policy development to facilitate appropriate data access, data sharing within the Agency and via data sharing agreements, as well as the appropriate reuse and repurposing of data to advance Agency regulatory science priorities?
- For stakeholders, including regulated industry, that submit data to FDA, how can FDA enhance the efficiency of the preparation and submission of data to FDA?
Individuals interested in presenting at and/or participating in a panel at the meeting should apply to do so by providing the information described in the Federal Register by January 28, 2020. Stakeholders who only wish to attend the public meeting in person must register by March 24, 2020. Lastly, stakeholders who intend to provide written feedback on this topic should submit written comments to the public docket by April 30, 2020.
Implications
The public meeting and docket represent the agency’s latest effort to deal with the rapid, ongoing uptick in the amount and complexity of data that increasingly informs regulatory decision-making. Interested stakeholders should take advantage of this opportunity to provide the agency with meaningful input on how best to update its existing data strategy.
Related Information
Members of the McDermott Digital Health team recently attended the Consumer Electronic Show, Digital Health event to explore digital health innovations and share insights on the many legal, regulatory and data specific implications that may be associated with these new health technologies. You can view the video takeaways below.

Flood and Terrorism Insurance Reauthorization: Safe For Now
ARTICLE
Flood and Terrorism Insurance Reauthorization: Safe For Now
January 14, 2020
Read time: 1 min
